Clinical trial of nafoxidine in advanced breast cancer.
Forty-nine postmenopausal patients with advanced breast cancer were treated with a nonsteroidal antiestrogen, Nafoxidine. The drug was generally well tolerated with dermatitis being the major toxic effect. A partial response in 12 of 40 patients, or 30%, was achieved with a median duration of response of greater than five months.
D000328:Adult; D000368:Aged; D001943:Breast Neoplasms / Q000188:drug therapy*; D004342:Drug Hypersensitivity / Q000209:etiology; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D008875:Middle Aged; D009256:Nafoxidine / Q000009:adverse effects / Q000627:therapeutic use*; D009362:Neoplasm Metastasis / Q000188:drug therapy; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy; D011241:Prednisone / Q000627:therapeutic use; D011759:Pyrrolidines / Q000627:therapeutic use*; D011960:Receptors, Estrogen / Q000187:drug effects
D011759:Pyrrolidines; D011960:Receptors, Estrogen; D009256:Nafoxidine; D011241:Prednisone